The U.S. FDA declined to approve a pre-filled syringe version of Regeneron Pharmaceuticals Inc.’s blockbuster eye drug Eylea.
Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.
Ann Arbor, Mich.-based Esperion Therapeutics reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.
Pfizer Inc.’s tafamidis reduced the risk of death for patients with a rare and fatal heart disease by around 30 percent, boosting the prospects of what could be a billion-dollar-a-year drug.
BioLineRx Ltd. announced the expansion of its immuno-oncology collaboration with Merck & Co. Inc. for the support of a Phase 2a program investigating BioLineRx’s BL-8040 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with metastatic pancreatic cancer.
AbbVie is taking another shot at solid tumor treatments through a collaboration with La Jolla, Calif.-based Calibr – a nonprofit drug discovery division of Scripps Research – to develop next-generation T-cell therapies that are aimed at targeting solid tumors.
AbbVie, a research-based global biopharmaceutical company, announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival.
Clinical data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of hemophilia B patients.
General Electric is diving deeper into the world of biotechnology. The conglomeration is launching prefabricated manufacturing units to product virus-based gene and cell therapies, Reuters reported.